CHEST Releases Expert Guideline for Lung Cancer Screening 
The American College of Chest Physicians (CHEST) recently published its new clinical guideline and expert panel report, titled "Screening for Lung Cancer: CHEST Guideline and Expert Panel Report," in the journal CHEST. The guideline contains 16 evidence-based recommendations and an update of the evidence base for the benefits, harms, and implementation of low-dose chest computed tomography screening. Read more.

FDA Approves First Targeted Treatment for NSCLC Patients With EGFR Mutations
The FDA announced the accelerated approval of Rybrevant (amivantamab-vmjw, Janssen Biotech) for the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. Read more.

No Clinical Benefit From Ipilimumab Plus Nivolumab in Squamous NSCLC
In previous phase lll studies, nivolumab plus ipilimumab given with and without chemotherapy enhanced survival compared with chemotherapy alone in patients with advanced non–small cell lung cancer (NSCLC). However, according to a phase lll trial published in JAMA Oncology, Gettinger et al indicated that adding ipilimumab to nivolumab did not improve survival in patients with advanced, previously treated, immunotherapy-naive squamous NSCLC. Read more.